Pentixapharm Unveils Promising CXCR4 Radiopharmaceutical Data at EANM 2025

Pentixapharm Holding AG has presented significant findings from its CXCR4 radiopharmaceutical platform at the EANM 2025 conference in Barcelona. The clinical data, derived from independent studies, underline the potential of [⁶⁸Ga]Ga-PentixaFor in diagnosing Primary Aldosteronism (PA), a condition often underdiagnosed despite its prevalence as a leading cause of secondary hypertension.

Results showcased at the conference highlight the efficacy of [⁶⁸Ga]Ga-PentixaFor PET/CT imaging in PA over traditional adrenal venous sampling, offering improved patient subtyping. In oncology, [¹⁷⁷Lu]Lu-PentixaTher demonstrated early therapeutic activity in bladder cancer, reinforcing CXCR4 as a crucial target in various diseases.

Dr. Dirk Pleimes, CEO of Pentixapharm, emphasized the importance of these findings in expanding the role of the CXCR4 platform across cardiovascular, endocrine, and oncologic disorders, marking a significant step in radiopharmaceutical innovation.